Tracy Murphy

1.8k total citations
29 papers, 463 citations indexed

About

Tracy Murphy is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Tracy Murphy has authored 29 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 10 papers in Public Health, Environmental and Occupational Health and 8 papers in Genetics. Recurrent topics in Tracy Murphy's work include Acute Myeloid Leukemia Research (20 papers), Acute Lymphoblastic Leukemia research (10 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Tracy Murphy is often cited by papers focused on Acute Myeloid Leukemia Research (20 papers), Acute Lymphoblastic Leukemia research (10 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Tracy Murphy collaborates with scholars based in Canada, United States and Australia. Tracy Murphy's co-authors include Karen Yee, Aaron D. Schimmer, Mark D. Minden, Steven M. Chan, Liran I. Shlush, Emily Heath, Neal S. Goldstein, Daniel D. De Carvalho, Parinaz Mehdipour and Hassan Sibai and has published in prestigious journals such as Blood, Science Advances and Pharmacology & Therapeutics.

In The Last Decade

Tracy Murphy

26 papers receiving 462 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tracy Murphy Canada 10 265 248 97 68 61 29 463
José González Spain 10 297 1.1× 365 1.5× 76 0.8× 37 0.5× 99 1.6× 25 507
Patricia Kropf United States 9 138 0.5× 193 0.8× 32 0.3× 70 1.0× 59 1.0× 26 341
Giovanni Marconi Italy 10 199 0.8× 166 0.7× 40 0.4× 61 0.9× 93 1.5× 58 360
Isabelle Luquet France 13 499 1.9× 195 0.8× 62 0.6× 159 2.3× 88 1.4× 45 636
Hyewon Lee South Korea 12 220 0.8× 127 0.5× 29 0.3× 88 1.3× 150 2.5× 38 424
Nita Williams United States 9 87 0.3× 274 1.1× 97 1.0× 32 0.5× 146 2.4× 23 461
Dmitriy Berenzon United States 13 301 1.1× 223 0.9× 73 0.8× 215 3.2× 99 1.6× 28 535
Tetsuichi Yoshizato Japan 10 312 1.2× 201 0.8× 62 0.6× 131 1.9× 37 0.6× 29 476
Maoxiang Qian China 11 189 0.7× 315 1.3× 93 1.0× 18 0.3× 118 1.9× 43 516

Countries citing papers authored by Tracy Murphy

Since Specialization
Citations

This map shows the geographic impact of Tracy Murphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tracy Murphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tracy Murphy more than expected).

Fields of papers citing papers by Tracy Murphy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tracy Murphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tracy Murphy. The network helps show where Tracy Murphy may publish in the future.

Co-authorship network of co-authors of Tracy Murphy

This figure shows the co-authorship network connecting the top 25 collaborators of Tracy Murphy. A scholar is included among the top collaborators of Tracy Murphy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tracy Murphy. Tracy Murphy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Culp‐Hill, Rachel, Andrea Arruda, Tracy Murphy, et al.. (2025). Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia. Blood. 146(21). 2589–2596.
2.
Richard‐Carpentier, Guillaume, Séverine Cathelin, Lisa Wang, et al.. (2025). Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial. The Lancet Haematology. 12(11). e887–e897.
3.
4.
5.
Chan, Steven M., Séverine Cathelin, Vikas Gupta, et al.. (2021). Enasidenib in Combination with Venetoclax in IDH2-Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial. Blood. 138(Supplement 1). 1263–1263. 13 indexed citations
6.
Puckrin, Robert, Eshetu G. Atenafu, Jaime O. Claudio, et al.. (2020). Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica. 106(1). 56–63. 28 indexed citations
7.
8.
Chen, Ruiqi, Arjun Law, Dawn Maze, et al.. (2020). Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen. Current Oncology. 28(1). 128–137.
9.
10.
Sibai, Hassan, Ruiqi Chen, Xing Liu, et al.. (2020). Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase‐based therapy. British Journal of Haematology. 191(5). 748–754. 14 indexed citations
11.
Murphy, Tracy, Brian Leber, Mark R. Bray, et al.. (2020). Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS. Blood. 136(Supplement 1). 1–2. 3 indexed citations
12.
Mehdipour, Parinaz, Tracy Murphy, & Daniel D. De Carvalho. (2019). The role of DNA-demethylating agents in cancer therapy. Pharmacology & Therapeutics. 205. 107416–107416. 33 indexed citations
13.
Chen, Ruiqi, Xing Liu, Dawn Maze, et al.. (2019). Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free Pediatric-Inspired ALL Regimen with Imatinib. Blood. 134(Supplement_1). 1303–1303. 1 indexed citations
14.
Lam, Wilson, Arjun Law, Tracy Murphy, et al.. (2019). Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience. Blood. 134(Supplement_1). 2609–2609. 1 indexed citations
15.
Murphy, Tracy, Andrea Arruda, Sze Wah Samuel Chan, et al.. (2019). PS961 PATIENTS WITH RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA HAVE SHORT REMISSION DURATION WITH RE‐INDUCTION: A SINGLE CENTER EXPERIENCE. HemaSphere. 3(S1). 432–433. 1 indexed citations
16.
Murphy, Tracy, Jinfeng Zou, Vikas Gupta, et al.. (2018). Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations. Blood. 132(Supplement 1). 992–992. 1 indexed citations
17.
Heath, Emily, Steven M. Chan, Mark D. Minden, et al.. (2017). Biological and clinical consequences of NPM1 mutations in AML. Leukemia. 31(4). 798–807. 125 indexed citations
18.
Murphy, Tracy & Karen Yee. (2017). Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert Opinion on Pharmacotherapy. 18(16). 1765–1780. 122 indexed citations
19.
Krawczyk, Janusz, Ronan Swords, Tracy Murphy, et al.. (2009). Clofarabine in the treatment of poor risk acute myeloid leukaemia. Hematological Oncology. 28(3). 118–123. 6 indexed citations
20.
Goldstein, Neal S. & Tracy Murphy. (1996). Intraductal Carcinoma Associated With Invasive Carcinoma of the Breast:A Comparison of the Two Lesions With Implications for Intraductal Carcinoma Classification Systems. American Journal of Clinical Pathology. 106(3). 312–318. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José González Breakdown of academic impact, for papers by Patricia Kropf Breakdown of academic impact, for papers by Giovanni Marconi Breakdown of academic impact, for papers by Isabelle Luquet Breakdown of academic impact, for papers by Hyewon Lee Breakdown of academic impact, for papers by Nita Williams Breakdown of academic impact, for papers by Dmitriy Berenzon Breakdown of academic impact, for papers by Tetsuichi Yoshizato Breakdown of academic impact, for papers by Maoxiang Qian
Rankless by CCL
2026